Health and Fitness

Reaction Biology’s Novel Approach to Oncology Drug Discovery

Reaction Biology, an industry-leading supplier of drug discovery companies, right now introduced that twelve abstracts highlighting information from the Company’s oncology drug discovery companies platform can be introduced on the American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022, in New Orleans, Louisiana.

Image Credit: afotostock/Shutterstock.com

“At AACR 2022, we look forward to showcasing data from our comprehensive suite of innovative drug discovery services that continue to support our clients in their oncology research goals,” stated Haiching Ma, Ph.D., Chief Scientific Officer of Reaction Biology. “With these data, we continue to build upon our capabilities as a world leader and partner in drug discovery.”

New information can be introduced on the Company’s diacylglycerol kinase assay panel, which is able to help researchers in higher informing isoform-specific inhibitor discovery and supplies researchers for the primary time with ten new lipid kinase targets. Additionally, Reaction will share information on a brand new biology strategy, resulting in an enhanced preclinical characterization of the WEE-1 inhibitor adavosertib.

Reaction will current information from quite a few new and enhanced assays and different drug discovery companies in oncology. The full vary of knowledge introduced at AACR embrace:

  • Development of diacylglycerol kinase assays to facilitate isoform-specific inhibitor discovery (Sunday, April 10, 2022, 1:30 PM – 5:00 PM; Poster Section 8, Poster Board Number: 24, Permanent Abstract Number: 170)
  • Characterization of KRas pathway inhibitors in 2D and 3D screening codecs (Sunday, April 10, 2022, 1:30 PM – 5:00 PM; Poster Section 23, Poster Board Number: 7, Permanent Abstract Number: 357)
  • Application of NanoBRET goal engagement mobile assay for measurement of inhibitor binding to wild kind and mutant RAS in stay cells (Sunday, April 10, 2022, 1:30 PM – 5:00 PM; Poster Section 24, Poster Board Number: 15, Permanent Abstract Number: 379)
  • Benefit of utilizing a spectral circulate analyzer for the evaluation of immune cell populations in tumors (Sunday, April 10, 2022, 1:30 PM – 5:00 PM; Poster Section 39, Poster Board Number: 14, Permanent Abstract Number: 629)
  • A methods biology strategy combining ProLiFiler and Cancer Data Miner for enhanced preclinical characterization of the WEE-1 inhibitor adavosertib (Monday, April 11, 2022, 9:00 AM – 12:30 PMPoster Section 24, Poster Board Number: 22, Permanent Abstract Number: 1132)
  • Comparison and penalties of various implantation strategies on the orthotopic progress of syngeneic Hepa1-6 liver most cancers cells (Monday, April 11, 2022, 1:30 PM – 5:00 PM; Poster Section 11, Poster Board Number: 13, Permanent Abstract Number: 1621)
  • Probing PRMT5 Inhibitors with Distinct Binding Modes Using Surface Plasmon Resonance (Tuesday, April 12, 2022, 9:00 AM – 12:30 PMPoster Section 40, Poster Board Number: 6, Permanent Abstract Number: 2921)
  • Exploring the combinatorial potential of bispecific T-cell engagers in excessive throughput format (Tuesday, April 12, 2022, 9:00 AM – 12:30 PMPoster Section 38, Poster Board Number: 8, Permanent Abstract Number: 2893)
  • Comprehensive characterization of CDK inhibitors utilizing an entire panel of all 20 human cyclin-dependent kinases (Tuesday, April 12, 2022, 9:00 AM – 12:30 PMPoster Section 5, Poster Board Number: 8, Permanent Abstract Number: 2304)
  • Real-time quantitative PCR primarily based evaluation of transcriptional results of CDK8/Cyclin C inhibitors (Tuesday, April 12, 2022, 9:00 AM – 12:30 PM; Poster Section 5, Poster Board Number: 22, Permanent Abstract Number: 2318)
  • A flexible assay suite for the invention of recent KRAS pathway inhibitors (Tuesday, April 12, 2022, 1:30 PM – 5:00 PM; Poster Section 4, Poster Board Number: 16, Permanent Abstract Number: 2987)
  • Cytotoxic results of LRRK2 inhibitors in mixed remedy with chemotherapeutic brokers on a big panel of most cancers cell strains (Wednesday, April 13, 2022, 9:00 AM – 12:30 PMPoster Section 27, Poster Board Number: 26, Permanent Abstract Number: 4072)

“This year, we celebrate the Company’s 20-year history of delivering superior science and driving customer-centric innovation, while we build upon our expanding suite of comprehensive services and support,” stated John H. Johnson, Chief Executive Officer and Director of Reaction Biology. 

These information at AACR characterize the breadth and depth of Reaction Biology’s pre-clinical analysis companies in oncology and underscore why we’re a most well-liked world accomplice within the space of drug discovery.

John H. Johnson, Chief Executive Officer and Director of Reaction Biology

Copies of the poster shows can be accessible at Reaction Biology’s sales space (#1247) throughout exhibit corridor hours April 10 – April 13 and on the Company’s web site.



Source hyperlink

Leave a Reply

Your email address will not be published.